Collegium Pharmaceutical (NASDAQ:COLL) Sets New 12-Month Low – Here’s What Happened

Collegium Pharmaceutical, Inc. (NASDAQ:COLL)’s stock price reached a new 52-week low on Tuesday . The company traded as low as $28.30 and last traded at $28.30, with a volume of 534 shares traded. The stock had previously closed at $28.62.

Analyst Ratings Changes

Several research firms have commented on COLL. StockNews.com downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 23rd. Piper Sandler reissued a “neutral” rating and issued a $37.00 target price on shares of Collegium Pharmaceutical in a report on Friday, October 11th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $42.60.

Collegium Pharmaceutical Price Performance

The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. The stock has a market cap of $945.25 million, a P/E ratio of 12.63 and a beta of 0.82. The firm has a 50 day moving average price of $30.73 and a 200 day moving average price of $34.07.

Hedge Funds Weigh In On Collegium Pharmaceutical

A number of institutional investors have recently modified their holdings of COLL. Penserra Capital Management LLC purchased a new stake in Collegium Pharmaceutical in the third quarter worth about $757,000. Squarepoint Ops LLC raised its stake in shares of Collegium Pharmaceutical by 194.5% during the 2nd quarter. Squarepoint Ops LLC now owns 110,338 shares of the specialty pharmaceutical company’s stock worth $3,553,000 after acquiring an additional 72,874 shares in the last quarter. Barclays PLC lifted its position in Collegium Pharmaceutical by 152.2% during the 3rd quarter. Barclays PLC now owns 75,052 shares of the specialty pharmaceutical company’s stock worth $2,899,000 after acquiring an additional 45,291 shares during the period. BOKF NA acquired a new position in shares of Collegium Pharmaceutical in the second quarter valued at about $490,000. Finally, Renaissance Technologies LLC raised its position in Collegium Pharmaceutical by 8.0% during the 2nd quarter. Renaissance Technologies LLC now owns 1,531,498 shares of the specialty pharmaceutical company’s stock worth $49,314,000 after buying an additional 113,300 shares during the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.